linjc16/ctgov huggingface dataset:
The Effect of Anesthetics Agents on Vascular Injury and Level of Syndecan-1 During Knee Surgery

Study Overview
=================
Brief Summary
-----------------
Ischeic reperfusion injury lead to a cellular dyfunction and increase in soluble glycocalyx of blood flow. syndecan-1 was a marker of glycocalyx. The purpose of this study is to prove the variation of level of serum syndecan-1 between preoperative and postoperative period.

Detailed Description
-----------------
The patients were allocated randomly to receive propofol or desflurane. Also, a total of 6ml of blood sample was obtained for total 6 times in consecutive order. Preoperation (immediate before anesthesia induction) Immediate before tourniquet off 5 min after tourniquet off PACU postoperative 6 hours postoperative 24 hours Serum in blood will be obtained and level of serum cytokine will be evaluated by enzyme-linked immunosorbent assay

Official Title
-----------------
The Effect of Anesthetics Agents on Vascular Injury and Level of Syndecan-1 During Knee Surgery

Conditions
-----------------
Ischemia

Intervention / Treatment
-----------------
* Drug: propofol group
* Drug: Desflurane group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who was planned to undergo knee surgery. Exclusion Criteria: age < 20 years old history of previous cancer history of previous peripheral vascular disease Emergency surgery

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: propofol group<br>The patient who anesthetized by using propofol. | Drug: propofol group<br>* Patient will be anesthetized by using propofol infusion during operation.<br>* Other names: Propofol;|
| Active Comparator: Desflurane group<br>The patient who anesthetized by using sevoflurane. | Drug: Desflurane group<br>* Patient will be anesthetized by using desflurane inhalation during operation.<br>* Other names: Desflurane;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Syndecan-1 | change of level of syndecan-1 (scores range from 0 to 100) | Preoperative time, Immediate before tourniquet off,5 min after tourniquet off,PACU, postoperation after 6hours, postoperation after 24hours |
PostPlacental IUD Insertion

Study Overview
=================
Brief Summary
-----------------
The immediate post cesarean section IUD insertion is a further step towards spreading more compliance to females in developing countries, with rapid increase in population size

Conditions
-----------------
Contraception

Intervention / Treatment
-----------------
* Device: Copper T intrauterine device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females desiring contraception by using intrauterine device following their vaginal delivery or cesarean section Exclusion Criteria: refusal to participate in the study desiring other methods of contraception will not use any method of contraception has a contraindication for the use of IUD as bicornuate or septate uterus, sub mucous myomas, etc.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PostPlacental IUD insertion<br>Copper T intrauterine device will be inserted immediately following delivery of the placenta in cases of cesarean section deliveries. | Device: Copper T intrauterine device<br> <br> * Other names: copper T IUD;|
| No Intervention: Control<br>IUD will be offered as a method of contraception after puerperium | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Expulsion rate |  | 6 months | 
| The percentage of females seeking contraception |  | 6 months |
Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the comparative bioavailability of three capsule formulations of MK-0974.

Official Title
-----------------
An Open Label, Randomized, 3-Period Crossover Study to Evaluate the Comparative Bioavailability of Variably Aged MK-0974 Capsules Administered Orally as Single Doses in Healthy Male and Female Subjects

Conditions
-----------------
Migraine

Intervention / Treatment
-----------------
* Drug: telcagepant potassium
* Drug: MK-0974 5Mo5C
* Drug: MK-0974 12Mo5C


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is in good health Subject is a nonsmoker Subject is willing to comply with the study restrictions Exclusion Criteria: Subject has a history of stroke, chronic seizures, or major neurological disorder Subject has a history of cancer Subject is a nursing mother Subject has or has a history of any illness that might make participation in the study unsafe or confound the results of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>MK-0974 12MoRT | Drug: telcagepant potassium<br>* [INTERVENTION NAME: MK-0974 12MoRT] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods<br>|
| Active Comparator: 2<br>MK-0974 5Mo5C | Drug: MK-0974 5Mo5C<br>* Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods<br>|
| Active Comparator: 3<br>MK-0974 12Mo5C | Drug: MK-0974 12Mo5C<br>* Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the curve (AUC(0 to infinity) following single dose administration of MK-0974 12Mo5C and 5Mo5C formulations |  | Through 48 hours postdose | 
| Peak plasma concentration (Cmax) following single dose administration of MK-0974 12Mo5C and 5Mo5C formulations |  | Through 48 hours postdose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the curve (AUC(0 to infinity) following single dose administration of MK-0974 12MoRT and 5Mo5C formulations |  | Through 48 hours postdose | 
| Peak plasma concentration (Cmax) following single dose administration of MK-0974 12MoRT and 5Mo5C formulations |  | Through 48 hours postdose |
Factors Predicting Postoperative Cesarean Section Pain

Study Overview
=================
Brief Summary
-----------------
In spite of identical analgesic protocols, parturients suffer different levels of pain postoperative lay. In this study we hope to identify factors which influence the perception of pain including preoperative anxiety, sleep quality and local anesthesia injection pain.

Official Title
-----------------
Analysis of Factors Predicting Postoperative Pain and Wound Hyperalgesia After Cesarean Section

Conditions
-----------------
Postoperative Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women undergoing spinal anesthesia Exclusion Criteria: women unable to cooperate Women undergoing general anesthesia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative pain |  | Postoperative day1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cesarean section, Wound hyperalgesia, Pain
SARS-CoV-2 Pre-exposure Prophylaxis With Ivermectin Retrospective Cohort Study

Study Overview
=================
Brief Summary
-----------------
This observational study, a multicenter retrospective cohort database study, carried out in two medical centers, Centro Medico Bournigal (CMBO) in Puerto Plata and Centro Medico Punta Cana (CMPC) in Punta Cana, Dominican Republic, sought to determine whether Ivermectin, at a weekly orally dose of 0.2 mg/kg, is an effective pre-exposure prophylactic method (PrEP) for the spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in the healthcare workers. The study began on June 29, 2020 and ended on July 26, 2020 (4 weeks).

Official Title
-----------------
Multicenter Retrospective Cohort Study of Ivermectin as a SARS-CoV-2 Pre-exposure Prophylactic Method in Healthcare Workers in Dominican Republic

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Drug: Ivermectin 6 Mg Oral Tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Active workers from Centro Medico Bournigal (CMBO) and Centro Medico Punta Cana (CMPC) during the study. Exclusion Criteria Workers with positive Covid-19 RT-PCR prior to the start of the study Those that did not take the first dose of Ivermectin the first week at the start of the study Those that did not complied with at least 2 out of 4 weekly doses Those that had greater than 14 days difference in days between two intakes Ivermectin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ivermectin Group<br>Healthcare personnel receiving Ivermectin weekly PrEP | Drug: Ivermectin 6 Mg Oral Tablet<br>* Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks<br>* Other names: Ivermectin;|
| Control Group<br>Healthcare personnel not receiving Ivermectin | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants RT-PCR positive for Covid-19 | Workers confirmed Covid-19 through Reverse Transcription Polymerase Chain Reaction (RT-PCR) test | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of sick participants who condition deteriorated | Workers infected with Covid-19, confirmed with RT-PCR and required hospitalization and/or ICU | 4 weeks | 
| Number of sick participants who died | Workers infected with Covid-19, confirmed with RT-PCR and died. | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ivermectin, SARS-CoV-2, Coronavirus, Prophylaxis, PrEP, Covid-19
Silo Versus Primary Closure for Gastroschisis

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to scientifically evaluate two different closure strategies for gastroschisis to determine if there is a difference in the two approaches.

Detailed Description
-----------------
The hypothesis is that there is no difference between bedside silo placement and operative closure in return of bowel function, ventilator dependence, or length of stay. The primary outcome variable between the two techniques will be length of hospitalization. The likely variables will be length of time to meet discharge criteria, length of hospitalization, time to full feedings, time on mechanical ventilation and total hospital charges.

Official Title
-----------------
Bedside Silo Versus Attempted Operative Closure for Gastroschisis

Conditions
-----------------
Gastroschisis

Intervention / Treatment
-----------------
* Procedure: silo for gastroschisis
* Procedure: Primary closure of gastroschisis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants with gastroschisis Exclusion Criteria: Born prior to 34 weeks estimated gestational age Another congenital anomaly influencing the respiratory status, gastrointestinal status, or the length of hospitalization and recovery. Inability to get parental permission before treatment.

Ages Eligible for Study
-----------------
Minimum Age: 5 Minutes
Maximum Age: 2 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: primary closure of gastroschisis<br>Attempt primary skin closure of gastroschisis shortly after birth | Procedure: Primary closure of gastroschisis<br>* Primary closure of gastroschisis, if possible<br>|
| Active Comparator: silo for gastroschisis<br>Surgical placement of silo over gastroschisis shortly after birth | Procedure: silo for gastroschisis<br>* silo placed around abdominal contents in gastroschisis patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of hospitalization | The length of time required for meeting discharge criteria | 1-6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gastroschisis, silo, primary closure
Eyenovia MiDD Usability Study

Study Overview
=================
Brief Summary
-----------------
This study is to evaluate the usability and patient tolerability for microtherapeutic dosing of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)

Official Title
-----------------
An Evaluation of the Usability and Patient Tolerability for Microtherapeutic Dosing of Commercially Available Ocular Medication Via the Eyenovia Microdose Delivery System (MiDD)

Conditions
-----------------
Intraocular Pressure

Intervention / Treatment
-----------------
* Drug: Latanoprost
* Drug: Latanoprost


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy patients without significant ocular pathology and mean unmedicated diurnal intraocular pressure (IOP) in the range of of 17-27 mmHg Willing to forego use of contact lenses during study period Presence of cognition an dexterity necessary to follow MiDD drug administration instructions Female subjects must be 1-year postmenopausal, surgically sterilized, or if of childbearing potential, have a negative serum pregnancy test Exclusion Criteria: Prior clinically significant ocular history or abnormal eye exam Use of ocular medication within 30 days of screening Use of oral steroid within 30 days of screening, or anticipated need for ocular steroid treatment during study period History of drug or alcohol abuse within 1 year of screening Lid squeezer Presence of disabling arthritis or limited motor coordination that would limit self-handling of the MiDD Participation in any interventional study of an investigational drug or device within 30 days of screening

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Microdose administration<br>Latanoprost ophthalmic solution administered as a microdose using the Eyenovia MiDD | Drug: Latanoprost<br>* Latanoprost ophthalmic solution administered as a microdose spray<br>|
| Active Comparator: Eyedrop administration<br>Latanoprost ophthalmic solution administered as an eyedrop | Drug: Latanoprost<br>* Latanoprost ophthalmic solution administered as an eyedrop<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful microtherapeutic administration to the ocular surface | Cumulative percent of cases in which microdose medication is delivered to the ocular surface as evaluated by the treating physician and an independent observer | Treatment Day 3 |
Using of Testes' Shocker in Improving Sexual Activity

Study Overview
=================
Brief Summary
-----------------
Using of testes' shocker in treating the sexual dysfunction.

Detailed Description
-----------------
Using of electrical shocks in treating sexual dysfunction in males, rectile dysfunction and inability to perform sexually good.

Official Title
-----------------
Using of Testes' Shocker in Treating Sexual Disease and Dysfunction

Conditions
-----------------
Sexual Dysfunction, Sexual Abstinence, Sexual Desire Disorder, Erectile Dysfunction, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Cryotherapy, Erectile Dysfunction With Diabetes Mellitus, Erectile Dysfunction Following Radiation Therapy, Erectile Dysfunction Following Urethral Surgery, Erectile Dysfunction With Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Device: JT Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with sexual dysfunction or erectile dysfunction Exclusion Criteria: Patients with trauma or other causes that make them inactive sexually

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Case control
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Case (Testes shocker device)<br>The shocker will be used in delivering the current gradually on the testes and penis to improve the blood flow and stimulates the sexual activity among males. | Device: JT Device<br>* Shocker giving electrical shocks on testes<br>* Other names: Testes shocker;|
| Sham Comparator: Control (non testes shocker device)<br>These groups will not given the shocks, shame device will be used instead and then compare the two results. | Device: JT Device<br>* Shocker giving electrical shocks on testes<br>* Other names: Testes shocker;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sexual desire | improving the desire of sex by using the electric shocks directly on the testes and penis. This will be assessed by a questionnaire (validated and reliable) to assess their ability to have sex more actively or not. | less than one month | 
| Erectile dysfunction | solving the problem of erectile dysfunction and this will be assessed by examination and experience to see if there is an effect for the electric shocks on erectile improvement. | less than one month |
Nutrient Levels Alter Transplant Outcome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to look at lipid profiles of plasma and RBC and amino acid profiles in plasma to determine if they are associated with allograft rejection, calcineurin inhibitor toxicity or new onset diabetes mellitus in renal transplant patients receiving dietary supplements with arginine and omega-3 fatty acids.

Official Title
-----------------
Role of Immunonutrient Levels in Preventing Complications After Renal Transplantation

Conditions
-----------------
Chronic Renal Disease

Intervention / Treatment
-----------------
* Dietary Supplement: Arginine and canola oil
* Dietary Supplement: Coromega and Arginine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Renal transplant recipient Appropriate blood samples drawn and analyzed
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Arginine and Canola oil supplemented group | Dietary Supplement: Arginine and canola oil<br>* Canola oil 1 tablespoon BID Arginine 9.0grams BID<br>* Other names: Arginaid;|
| Experimental: 2<br>Arginine and Coromega | Dietary Supplement: Coromega and Arginine<br>* Arginine 9.0 grams BID Coromega dose based on weight<br>* Other names: Arginaide;|
| No Intervention: 3<br>Control | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma and red blood cell lipid profiles |  | Within 1 year | 
| Plasma amino acid profiles |  | within 1 year |